StemCell Therapy

BOCA RATON, Fla., Feb. 14, 2025 (GLOBE NEWSWIRE) -- Entero Therapeutics, Inc. (Nasdaq: ENTO) (“Entero” or the “Company”), a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases, announced today that the board of directors has appointed Mr. Richard Paolone as the interim CEO of the Company.

Original post:
Entero Therapeutics Appoints Richard Paolone as CEO

SAN FRANCISCO, Feb. 14, 2025 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines, the next frontier in innovative drug design aimed at improving treatment options for patients with cancer and inflammatory diseases, today announced that on February 11, 2025, the company granted inducement awards to nine new employees. The grants were made pursuant to Nurix’s 2024 Equity Inducement Plan as an inducement material to the employees’ acceptance of employment with Nurix and were approved by the Compensation Committee of Nurix’s Board of Directors in accordance with Nasdaq Listing Rule 5635(c)(4).

See the article here:
Nurix Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

TORONTO and HAIFA, Israel, Feb. 14, 2025 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (Germany: J90) (“NurExone” or the “Company”) is excited to announce that it will be presenting at the International Society for Cell & Gene Therapy (ISCT) 2025 Annual Meeting (“ISCT 2025”), a major global cell and gene therapy translation conference, taking place from May 7-10, 2025 in New Orleans, Louisiana, United States.

See original here:
NurExone Biologic Continues Expansion of U.S. Presence and Awareness with Prestigious Conference Presentation

- Data from DELIVER and ACHIEVE Clinicals Trial to be Presented -

Read the original post:
Dyne Therapeutics Announces Upcoming Presentations at the 2025 MDA Clinical & Scientific Conference

TORONTO, Feb. 14, 2025 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseases, today reported financial results for the three months ended December 31, 2024 and provided an update on its business.

Visit link:
Edesa Biotech Reports Fiscal 1st Quarter 2025 Results

CARLSBAD, Calif., Feb. 14, 2025 (GLOBE NEWSWIRE) -- Natural Alternatives International, Inc. ("NAI") (Nasdaq: NAII), a leading formulator, manufacturer, and marketer of customized nutritional supplements, today announced a net loss of $2.2 million, or $0.37 per diluted share, on net sales of $34.1 million for the second quarter of fiscal year 2025 compared to a net loss of $3.1 million, or $0.52 per diluted share, in the second quarter of the prior fiscal year.

Continue reading here:
Natural Alternatives International, Inc. Announces 2025 Q2 and YTD Results

COPENHAGEN, Denmark, February 14, 2025 – Bavarian Nordic A/S (OMX: BAVA) announced today that the U.S. Food and Drug Administration (FDA) has approved VIMKUNYA™ (Chikungunya Vaccine, Recombinant) for injection, the first virus-like particle (VLP) single-dose chikungunya vaccine in the U.S. for persons 12 years of age and older.

Here is the original post:
Bavarian Nordic Receives U.S. FDA Approval of Chikungunya Vaccine for Persons Aged 12 and Older

WARREN, N.J., Feb. 14, 2025 (GLOBE NEWSWIRE) -- Ryan Saadi, MD, MPH, Founder and CEO of Tevogen Bio (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech company, reaffirms his commitment to preserving equity for shareholders. Amid ongoing discussions about financing approaches in the biotech sector, Dr. Saadi emphasizes his distinct strategy, which prioritizes efficiency, asset ownership, and a path to revenue.

Read more:
Tevogen Bio CEO Reinforces Commitment to Retention of Equity Capital and Long-Term Vision

MENLO PARK, Calif., Feb. 14, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading provider of high-quality, highly accurate sequencing platforms, today announced that the Compensation Committee of the Company’s Board of Directors granted a non-qualified stock option (the “Option”) covering 400,000 shares of PacBio common stock, and restricted stock units (“RSUs”) covering 300,000 shares of PacBio common stock to a recently hired employee under the Pacific Biosciences 2020 Inducement Equity Incentive Plan (the “2020 Inducement Plan”), effective on February 10, 2025. The award was granted as an inducement material to such individual’s entering into employment with PacBio in accordance with Nasdaq Marketplace Rule 5635(c)(4).

Go here to read the rest:
PacBio Grants Equity Incentive Award to New Employee

Effect of Bio MTA plus & ProRoot MTA pulp capping materials on the regenerative properties of human dental pulp stem cells  Nature.com

Read more:
Effect of Bio MTA plus & ProRoot MTA pulp capping materials on the regenerative properties of human dental pulp stem cells - Nature.com

Graphics for Hospitals and Health Systems Stakeholder Letter.

Use the suggested stakeholder letter to speak to a hospital/health system audience about the impact of Preventive Medicine and how preventive medicine physicians provide value and demonstrate cost savings by providing the knowledge, skills, and expertise to fill multiple roles within a single position.

Here is the original post:
This is Preventive Medicine Toolkit - ACPM

In a Historic First, Arete Health Partners with InsideTracker to Bring Preventative Health Care as a Covered Benefit for Its Members Turning Sick Care into Health Care  Business Wire

Read the original:
In a Historic First, Arete Health Partners with InsideTracker to Bring Preventative Health Care as a Covered Benefit for Its Members Turning Sick Care...

Arkansas kids and tooth decay: Why prevention matters  Jonesboro Sun

Read this article:
Arkansas kids and tooth decay: Why prevention matters - Jonesboro Sun

Prevention and a community focus are integral to general practice  The BMJ

Read the original post:
Prevention and a community focus are integral to general practice - The BMJ

Prenuvo Announces it Had Raised $120M to Advance Preventative Health, Launches Novel FDA-Cleared AI-Powered Products  Business Wire

Read this article:
Prenuvo Announces it Had Raised $120M to Advance Preventative Health, Launches Novel FDA-Cleared AI-Powered Products - Business Wire

Vaccination Is Key To Disease Prevention  The Tomahawk

Read more:
Vaccination Is Key To Disease Prevention - The Tomahawk

What's happening with the anti-HIV program PEPFAR? It depends whom you ask  KNKX Public Radio

Read more:
What's happening with the anti-HIV program PEPFAR? It depends whom you ask - KNKX Public Radio

Gender and Healthcare Ownership in Hypertension and Cardiovascular Prevention  Physician's Weekly

See the article here:
Gender and Healthcare Ownership in Hypertension and Cardiovascular Prevention - Physician's Weekly

This Louisiana doctor shares timeline of health screenings that could save lives  NOLA.com

More here:
This Louisiana doctor shares timeline of health screenings that could save lives - NOLA.com

DNA Health & Wellness Brings Advanced Preventative Health and Longevity Solutions to the Capital  PR Newswire

Excerpt from:
DNA Health & Wellness Brings Advanced Preventative Health and Longevity Solutions to the Capital - PR Newswire